Goldman Sachs Group upgraded shares of H. Lundbeck A/S- (OTCMKTS:HLUYY) from a sell rating to a neutral rating in a research report report published on Tuesday, The Fly reports.
HLUYY has been the subject of a number of other reports. Credit Suisse Group reissued an underperform rating on shares of H. Lundbeck A/S- in a research note on Friday, August 14th. AlphaValue lowered shares of H. Lundbeck A/S- to a buy rating in a research note on Friday, August 21st. UBS Group reaffirmed a buy rating on shares of H. Lundbeck A/S- in a research note on Monday, August 17th. Zacks Investment Research raised shares of H. Lundbeck A/S- from a hold rating to a buy rating and set a $36.00 price objective for the company in a research note on Friday, September 11th. Finally, Barclays reissued an overweight rating on shares of H. Lundbeck A/S- in a research report on Friday, August 14th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the company. H. Lundbeck A/S- currently has a consensus rating of Hold and an average target price of $36.00.
H. Lundbeck A/S- stock traded up $0.77 during midday trading on Tuesday, reaching $33.47. 3,323 shares of the stock were exchanged, compared to its average volume of 3,395. The company has a debt-to-equity ratio of 0.77, a quick ratio of 0.80 and a current ratio of 1.10. H. Lundbeck A/S- has a 52 week low of $25.68 and a 52 week high of $44.60. The company’s fifty day moving average is $34.46 and its 200-day moving average is $35.08.
H. Lundbeck A/S- Company Profile
H. Lundbeck A/S engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, North America, and internationally. The company's principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for treating symptomatic neurogenic orthostatic hypotension; Onfi for Lennox-Gastaut syndrome; and Rexulti to treat depression/schizophrenia.
Recommended Story: How are dividend achievers different from dividend aristocrats?
Receive News & Ratings for H. Lundbeck A/S- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for H. Lundbeck A/S- and related companies with MarketBeat.com's FREE daily email newsletter.